Thomas Niel

Thomas Niel

InvestorPlace Contributor

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

Ocugen Stock May Have One More Rally in It Before It’s Over

By Thomas Niel, InvestorPlace Contributor

Long-term prospects for OCGN stock remain unclear, but its Covid-19 catalyst could fuel another spike in the short-term.

Crypto Mining Stocks Are Risky, but SOS Ltd Stock Takes the Cake

By Thomas Niel, InvestorPlace Contributor

Bottom line: crypto mining stocks overall are risky. But, with the aforementioned red flags, SOS stock takes the cake, so stay away.

Even With the EV Sector Rebound, Nio Stock Could Head Lower

By Thomas Niel, InvestorPlace Contributor

Sure, it's still early to say that its recent rebound is merely a "dead cat bounce." But, weighing the risk of further losses, against the possibility of a continued rebound, it's best to skip out on NIO stock for now.

Zomedica Stock Could Hold Steady, but It’s Hardly a Buy at Today’s Prices

By Thomas Niel, InvestorPlace Contributor

Nevertheless, with little reason for it to rally further, but with it still vulnerable to another move lower, skip out on ZOM stock, and look elsewhere for high-risk, but high-potential, opportunities.

8 Biotech Penny Stocks for Investors to Watch

By Thomas Niel, InvestorPlace Contributor

Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.

Stand Clear as Sundial Growers Stock Seems Destined to Keep Plummeting

By Thomas Niel, InvestorPlace Contributor

So, with 'meme stock mania' fading, and the likelihood of federal legalization in the near-term also fading, what's the best move regarding SNDL stock? Until shares fall to a more reasonable valuation (under $1 per share), continue to avoid it.

Despite Recent Deal Close, It’s Too Early to Buy ChargePoint Stock

By Thomas Niel, InvestorPlace Contributor

Trending lower after its SPAC merger, take your time with EV charging play CHPT stock when it comes to entering a long-term position.

Ideanomics Stock Could Stay Strong, But It’s Not the Best EV Play

By Thomas Niel, InvestorPlace Contributor

Instead of taking a gamble with questionable odds, stick with the more focused electric vehicle plays out there, and skip out on IDEX stock.

Stay Away — Workhorse Stock Still Has More Room to Fall

By Thomas Niel, InvestorPlace Contributor

After losing the USPS bid, there's little reason to buy fading EV truck play WKHS stock as it heads towards lower price levels.

Until Bitcoin Trends Lower, Don’t Bet Against Marathon Digital Stock

By Thomas Niel, InvestorPlace Contributor

If crypto prices crash, expect MARA stock to make larger declines than Bitcoin itself. With this in mind, sticking to cryptos directly remains the best play.

Load More